Our Pricing

Wegovy Starter to Highest Dose: Complete Journey

Published on: June 03, 2026

Understanding the wegovy starter to highest dose uk pathway is essential for successful weight management outcomes. At Cured Pharmacy, our UK-registered clinical team guides patients through the complete dose escalation from 0.25mg to the maintenance 2.4mg dose, ensuring safe titration and optimal tolerability. This structured approach, validated in the STEP clinical trial programme, minimises gastrointestinal side effects whilst maximising weight loss results [1].

Why Wegovy Requires Gradual Dose Escalation

Wegovy (semaglutide) follows a medically validated titration schedule over 16-20 weeks to reach the therapeutic 2.4mg maintenance dose [1]. This gradual escalation isn't arbitrary — it allows your digestive system to adapt to semaglutide's effects on gastric emptying and appetite regulation, significantly reducing the risk of nausea, vomiting, and treatment discontinuation.

Clinical data from the STEP-1 trial demonstrated that patients following the structured dose escalation achieved an average 14.9% body weight reduction over 68 weeks, with 86% completing the full titration schedule [1]. Patients who attempt to skip doses or escalate too quickly experience substantially higher rates of gastrointestinal adverse events, often leading to treatment abandonment.

The MHRA-approved titration protocol balances efficacy with tolerability. Each dose level serves a specific purpose: lower doses initiate metabolic changes and allow your body to adjust, whilst higher doses deliver the full therapeutic effect on weight regulation pathways in the brain and gut [2].

The Complete Wegovy Dosing Schedule: Week by Week

Your wegovy starter to highest dose uk journey follows five distinct phases, each lasting four weeks. Month 1 begins with the 0.25mg starter dose, administered once weekly via subcutaneous injection. This initial dose establishes baseline tolerance and begins appetite modulation without overwhelming your system.

Month 2 progresses to 0.5mg weekly. Many patients notice their first significant appetite changes at this stage, with reduced food cravings and earlier satiety signals during meals [1]. Month 3 introduces the 1mg dose, where weight loss typically accelerates as semaglutide reaches more substantial plasma concentrations.

Month 4 advances to 1.7mg weekly — a critical transition point where some patients experience temporary increases in nausea if they've progressed too quickly from the previous dose. Your UK prescriber may recommend remaining at 1mg for an additional four weeks if tolerability concerns arise. Month 5 reaches the maintenance 2.4mg dose, which you'll continue long-term for sustained weight management [2].

What Happens If You Miss a Dose During Escalation?

If you miss a Wegovy injection and it's been fewer than five days since your scheduled dose, administer it as soon as you remember. If more than five days have passed, skip that dose entirely and resume your regular schedule with the next injection [2]. Missing multiple doses during the escalation phase may require restarting at a lower dose level — your UK prescriber will assess your individual situation and determine the safest approach to resume treatment.

Managing Side Effects at Each Dose Level

Gastrointestinal side effects — primarily nausea, occasional vomiting, diarrhoea, and constipation — are most common during the first 48-72 hours after each dose increase [1]. These effects typically diminish within one to two weeks as your body adapts to the new dose level.

At the 0.25mg and 0.5mg starter doses, side effects are generally mild. Approximately 20% of patients report transient nausea, usually managed with smaller, more frequent meals and avoiding high-fat foods [2]. The 1mg dose represents the first significant jump in semaglutide exposure — about 44% of patients in clinical trials reported nausea at this level, though most cases resolved within 10-14 days.

The transitions to 1.7mg and 2.4mg carry the highest risk of gastrointestinal symptoms. Staying well-hydrated, eating slowly, and stopping when comfortably satisfied (rather than full) substantially improves tolerability. If side effects become severe or persist beyond two weeks at any dose, contact your prescriber immediately — you may benefit from extending that dose phase before progressing further.

When to Contact Your UK Prescriber

Seek immediate medical advice if you experience severe abdominal pain (especially upper right quadrant pain, which may indicate gallbladder issues), persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to the back), or symptoms of thyroid tumours (lump in neck, hoarseness, difficulty swallowing) [2]. These are rare but serious adverse events requiring prompt clinical assessment.

Expected Weight Loss at Each Wegovy Dose Stage

Weight loss during the wegovy starter to highest dose uk journey follows a predictable pattern, though individual results vary based on baseline BMI, dietary adherence, and physical activity levels. During months 1-2 (0.25mg and 0.5mg doses), expect modest weight reduction of 2-4% of baseline body weight — primarily driven by reduced caloric intake from appetite suppression [1].

Months 3-4 (1mg and 1.7mg doses) typically produce accelerated weight loss of 6-10% of baseline weight as semaglutide reaches therapeutic plasma concentrations. The STEP-1 trial data showed that by week 16 (when patients reached 1.7mg), average weight loss was approximately 9.6% [1].

The maintenance 2.4mg dose, continued from month 5 onwards, delivers the full therapeutic effect. In clinical trials, patients maintaining the 2.4mg dose for 68 weeks achieved an average 14.9% total body weight reduction, with some individuals losing over 20% [1]. Weight loss plateaus typically occur around month 9-12, after which continued treatment maintains the achieved weight reduction and prevents regain.

Wegovy Starter to Highest Dose UK: Cost Considerations

At Cured Pharmacy, Wegovy is available from £79.00 per month across all dose strengths, with transparent upfront pricing shown before your free clinical consultation. Unlike some providers who charge premium rates for higher doses, our pricing remains consistent whether you're on the 0.25mg starter dose or the 2.4mg maintenance dose.

The complete dose escalation journey represents a minimum five-month commitment to reach therapeutic levels, with most patients continuing long-term for sustained weight management. All Wegovy prescriptions require ongoing clinical supervision by a UK-registered prescriber, who will monitor your progress, assess tolerability, and adjust your treatment plan as needed.

Your initial online consultation takes under three minutes and is completely free. Our UK clinical team reviews your medical history, current medications, and weight loss goals to determine if Wegovy is appropriate for your individual circumstances. If approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging.

What's Included in Your Wegovy Treatment Plan

Every Wegovy prescription from Cured Pharmacy includes four pre-filled injection pens (one month's supply), detailed injection technique guidance, side effect management resources, and ongoing prescriber support. You'll receive email reminders before each dose escalation, with information on what to expect at the next level and when to contact your clinical team if concerns arise.

Staying on the Highest Dose: Long-Term Wegovy Maintenance

Once you reach the 2.4mg maintenance dose, your UK prescriber will recommend continuing this dose indefinitely for sustained weight management. Clinical trial data demonstrates that discontinuing Wegovy typically results in gradual weight regain — the STEP-4 trial showed that patients who stopped treatment after 20 weeks regained approximately two-thirds of their lost weight within 48 weeks [2].

Long-term maintenance at 2.4mg weekly provides continued appetite regulation, reduced food cravings, and metabolic benefits beyond weight loss alone. Many patients report sustained improvements in blood pressure, lipid profiles, and glycaemic control even after weight loss plateaus [1].

Your UK prescriber will schedule regular clinical reviews every 3-6 months to assess ongoing appropriateness of treatment, monitor for adverse effects, and ensure you're achieving meaningful clinical benefit. If weight loss is insufficient (less than 5% body weight reduction after 6 months at the maintenance dose), your prescriber may discuss alternative treatment options or adjunctive interventions to optimise outcomes.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
4. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
5. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy (semaglutide) is a prescription-only medicine in the UK and must be prescribed by a qualified clinician following appropriate clinical assessment.